| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| MNTA | Momenta Pharmaceuticals, Inc. | $27.4 | $2.15B | N/A |
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4260113-momenta-pharmaceuticals-inc-mnta-ceo-craig-wheeler-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare
May 05, 2019 - Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Q1 2019 Earnings Conference Call May 02, 2019, 08:30 ET Company Participants Patricia Eisenhaur - VP, IR & Communications Craig Wheeler - President, CEO
0
Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/05/02/momenta-pharmaceuticals-inc-mnta-q1-2019-earnings.aspx?source=iedfolrf0000001
May 02, 2019 - MNTA earnings call for the period ending March 31, 2019.
0
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
http://www.zacks.com/stock/news/403482/momenta-pharmaceuticals-mnta-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release?cid=CS-ZC-FT-403482
Apr 25, 2019 - Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
http://www.zacks.com/stock/news/365815/novartis-nvs-receives-fda-approval-for-ms-drug-mayzent?cid=CS-ZC-FT-365815
Mar 27, 2019 - Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
0
Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat
http://www.zacks.com/stock/news/356858/momenta-mnta-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-356858
Feb 25, 2019 - Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
0
Momenta Pharmaceuticals (MNTA) Q4 2018 Earnings Conference Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/02/22/momenta-pharmaceuticals-mnta-q4-2018-earnings-conf.aspx?source=iedfolrf0000001
Feb 22, 2019 - MNTA earnings call for the period ending December 31, 2018.
0
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4243338-momenta-pharmaceuticals-inc-mnta-ceo-craig-wheeler-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare
Feb 22, 2019 - Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Q4 2018 Earnings Conference Call February 22, 2019, 08:30 ET Company Participants Patty Eisenhaur - VP, Investor Relations and Corporate Communications Crai
0
Momenta Pharmaceuticals (MNTA) Reports Q4 Loss, Tops Revenue Estimates
http://www.zacks.com/stock/news/356593/momenta-pharmaceuticals-mnta-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-356593
Feb 22, 2019 - Momenta (MNTA) delivered earnings and revenue surprises of 84.78% and 102.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
0
Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for
http://www.zacks.com/stock/news/355122/analysts-estimate-momenta-pharmaceuticals-mnta-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-355122
Feb 15, 2019 - Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Here's Why Momenta Pharmaceuticals Fell for a Second Straight Day
https://www.fool.com/investing/2018/12/11/heres-why-momenta-pharmaceuticals-fell-for-a-secon.aspx?source=iedfolrf0000001
Dec 11, 2018 - Volatility strikes the biotech.
0
Page 1>